Cardiovascular Drugs and Therapy

, Volume 7, Issue 6, pp 929–934

Exercise tolerance in angina is improved by mivazerol—An alpha2-adrenoceptor agonist

  • Robert Anthony Wright
  • Philippe Decroly
  • Tatiana Kharkevitch
  • Michael F. Oliver


In a double-blind, placebo-controlled, randomized trial of treadmill exercise tolerance in six patients with chronic stable angina, intravenous mivazerol 1 µg, 2 µg, and 3 µg/kg increased in the time to onset of angina by 39%, 48%, and 76%; the time to 1-mm ST depression by 36%, 76%, and 104%; and total exercise duration by 15%, 23%, and 30%, respectively. In a subsequent double-blind, placebo-controlled, randomized trial involving a further 12 patients, a single oral dose of mivazerol of 800 µg, 1200 µg, and 1600 µg increased the time to onset of angina by 4%, 11%, and 30%; the time to 1-mm ST depression by 33%, 43%, and 53%; and the total exercise duration by 10%, 18%, and 23%, respectively. Mivazerol is an imidazole derivative with agonist properties at the alpha2-adrenoceptor and appears to be an effective antianginal. Mivazerol may improve exercise performance by attenuating the effects of exercise-induced sympathetic nervous system activity on the ischemic myocardium.

Key Words

mivazerol alpha2 adrenoceptor angina exercise tolerance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maseri A. Medical therapy of chronic stable angina pectoris.Circulation 1990;82:2258–2262.PubMedGoogle Scholar
  2. 2.
    Kharkevitch T, Guyaux M, Gobert J, Wulfert E. Mivazerol. A new α2-receptor agonist reduces ischaemia produced by coronary occlusion in rats and dogs.Cardiovasc Drugs Ther 1991;5:S407.Google Scholar
  3. 3.
    Kharkevitch T, Noyer M, Guyaux M, Riemersma RA, Gobert JK, Wulfert E. Mivazerol, a new α2-adrenergic agonist with anti-ischaemic effects in animal models of myocardial ischaemia. In:Proc Eur Assoc Cardiothorac Anaesthesiologists, 1992.Google Scholar
  4. 4.
    Du XJ, Hoet B, Kharkevitch T, Riemersma RA. Mivazerol inhibits neuronal norepinephrine release during myocardial ischaemia.J Mol Cell Cardiol 1992;24:S21.Google Scholar
  5. 5.
    Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards of evaluation.Ann Clin Res 1971;3:323–332.PubMedGoogle Scholar
  6. 6.
    Prichard BNC, Aelling WH, Richardson GA. The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: The effect on heart rate and the electrocardiogram.Postgrad Med J 1970;43(Nov suppl):77–83.Google Scholar
  7. 7.
    Subramanian VB, Bowles MJ, Khurmi NS, Davies AB, Raftery EB. Randomised double-blind comparison of verapamil and nifedipine in chronic stable angina.Am J Cardiol 1982;50:696–703.PubMedGoogle Scholar
  8. 8.
    Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in the treatment of angina pectoris.Circulation 1980;62:491–502.PubMedGoogle Scholar
  9. 9.
    Cocco G, Strozzi C, Haeusler G, Chu D, Amrein R, Padovan GC. The therapeutic value of clonidine in patients with coronary heart disease.Eur J Cardiol 1979;10:221–228.PubMedGoogle Scholar
  10. 10.
    Thomas MG, Quiroz AC, Rice JC, Sander GE, Giles TD. Anti-anginal effects of clonidine.J Cardiovasc Pharmacol 1986;8(Suppl 3):S69-S75.Google Scholar
  11. 11.
    Simoons ML, Tummers J, van Meurs-van Woezik H, van Domurg R. Alinidine, a new agent which lowers heart rate in patients with angina pectoris.Eur Heart J 1982;3:542–545.PubMedGoogle Scholar
  12. 12.
    Schurmans J, Piessens J, Kesteloot H, De Geest H. Comparative effects of alinidine and propranolol in ischaemic heart disease.Eur J Clin Pharmacol 1982;23:389–396.PubMedGoogle Scholar
  13. 13.
    Meinertz T, Kasper W, Meier R, et al. Alinidine in angina.Clin Pharmacol Ther 1983;34:770–776.PubMedGoogle Scholar
  14. 14.
    Mohrman DE, Feigl EO. Competition between sympathetic vasoconstriction and metabolic vasodilation in the canine coronary circulation.Circ Res 1978;42:79–86.PubMedGoogle Scholar
  15. 15.
    Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog.Circ Res 1983;53:8–15.PubMedGoogle Scholar
  16. 16.
    Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross J Jr. Intracoronary α2-adrenergic receptor blockade attenuates ischaemia in conscious dogs during exercise.Circ Res 1988;62:536–542.Google Scholar
  17. 17.
    Kitakaze M, Hori M, Gotoh K, et al. Beneficial effects of α2-adrenoceptor activity on ischaemic myocardium during coronary hypoperfusion in dogs.Circ Res 1989;65:1632–1645.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Robert Anthony Wright
    • 1
  • Philippe Decroly
    • 2
  • Tatiana Kharkevitch
    • 2
  • Michael F. Oliver
    • 1
  1. 1.Cardiovascular Research UnitUniversity of EdinburghScotland
  2. 2.UCB SA, Pharma SectorBrusselsBelgium
  3. 3.Department of CardiologyRoyal InfirmaryEdinburghScotland

Personalised recommendations